ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients
RLT_Angels Photo
Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.
Wiesbaden, June 21, 2025 – The International Centers for Precision Oncology (ICPO) Foundation announced yesterday its role as a founding member of the RLT Angels Association together with leading organizations in the field of radiotheranostics namely the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company. The initiative, launched on June 20, 2025, carries the mission to improve the experience and availability of radioligand imaging (RLI) and radioligand therapies (RLT) for up to one million patients globally and expand capacity to one thousand RLT Centers. Drawing on world-leading expertise, RLT Angels aims to develop open-source best practice resources such as global blueprints and tools for process optimization to support healthcare providers. Building upon its global network of Centers of Excellence and online educational platform, the ICPO Foundation sets a standard for the RLT Angels Association with respect to the accreditation harmonization of theranostics centers and to the access and scaling of certified theranostics education. The initiative will be guided by an experienced board, including Prof. Richard P. Baum for ICPO, and supported by an independent, international Scientific Advisory Board comprised of leading clinical, economic, scientific and policy experts.
The ICPO Foundation co-founding the RLT Angels Association highlights the willingness from both organizations to mutually reinforce their respective mission and sustainably grow global patient access. Thanks to strong alignment on clinical best practices, educational needs and patient outcomes, ICPO Centers of Excellence (CoE) will benefit from new resources such as medical evidence and patient advocacy, and enhance their visibility towards additional referrals and industry collaborations. The RLT Angels Association will leverage the established and active ICPO CoEs network as well as ICPO's growing educational program and global community reach out including with patient associations.
Radiotheranostics utilizes diagnostic RLI and targeted RLT to identify and fight cancer, offering precise treatment that preserves healthy tissues. RLT has demonstrated benefits in clinical trials, and commercially approved therapies are available for certain neuroendocrine tumors (NETs) and prostate cancer.1,2 With approximately 225 ongoing clinical trials, use of RLI and RLT has the potential to expand to more than 15 cancer indications, significantly increasing the number of patients who could benefit from this innovative precision-based approach.3,4
Effective delivery of radiotheranostics requires seamless coordination across supply chains, radio-safety, operational, and clinical domains. As the demand for imaging and RLT treatments continues to grow, health systems must enhance their infrastructure, processes, capacity, and skills to meet this increasing need. To address these challenges and fully realize the potential of this promising treatment modality, stakeholders across the healthcare ecosystem have united in a collaborative effort to form the RLT Angels Association.
'As a founding member of RLT Angels, the ICPO Foundation believes in the power of partnership and mission alignment to drive meaningful change in healthcare. By leveraging our collective expertise – including ICPO's education and accreditation resources, as well as our global community outreach – we can enhance accessibility and ensure that innovative therapies reach those who need them most,' said Prof. Richard P. Baum, Trustee of the ICPO Foundation and President of the ICPO Academy for Theranostics.
A 'Center Recognition Program' will enable RLT Centers to measure their efficiency and quality of care. Additionally, RLT Angels will provide virtual support and online expert forums to help centers efficiently leverage these resources. The program will support centers to reach accreditation levels as defined by national and international medical societies, as well as by international non-profit organizations pursuing accreditation efforts. RLT Angels will enable standardized data collection to support evidence generation and advocacy initiatives to engage policy stakeholders and the broader public.
'The formation of RLT Angels Association marks a significant milestone in the evolution of Radioligand Therapy. Our commitment to collaboration will help bridge gaps in care and foster a community dedicated to improving patient outcomes through innovative practices.' said Prof. Paola Anna Erba, president of EANM.
Ben Hickey, president of RayzeBio, commented: 'RLT Angels represents an important multidisciplinary effort bringing together diverse expertise to address the challenges in delivering Radioligand or Radiopharmaceutical Therapy, and ensuring the full potential of this promising modality can be realized. We believe our collective efforts will pave the way for a more seamless treatment experience, increased operational efficiency and most importantly, improved clinical outcomes for patients.'
"We are proud to co-found RLT Angels. This ambitious organization will make a significant and positive impact on healthcare systems and patients, ensuring that the promise of RLT is not hindered by operational barriers. We at Novartis are dedicated to this field as an essential new pillar of Oncology and have long term plans and a deep commitment to every aspect in this area which can lead to better care" commented Dr Zsuzsanna Devecseri, Global Head, Medical Affairs Oncology, at Novartis.
Dr Ben Newton, Global Head of Oncology, GE HealthCare commented: 'Theranostics is a highly innovative treatment modality that requires the seamless integration of advanced imaging, radiopharmaceuticals, digital and clinical workflows, along with operational excellence. Successful integration into everyday practice depends on close collaboration across leading healthcare providers, scientists, industry, and patient advocacy groups. We are proud to be a founding member of RLT Angels and to contribute to this collective effort to advance global access to RLT and improve outcomes for patients across the globe.'
To learn more about the RLT Angels Association and explore opportunities for involvement, please visit the website at www.rlt-angels.com or our LinkedIn page. RLT Angels is seeking like-minded partners dedicated to enhancing patient care and improving access to radiotheranostics.
About RLT Angels RLT Angels is a non-profit organization dedicated to maximizing patient access to radiotheranostics, systematically expanding health system capacity to deliver radioligand imaging (RLI) and radioligand therapies (RLT), and improving the experience and outcomes for patients receiving this treatment globally. Our objective is to deliver on the promise of the treatment modality and maximize patient access.
About ICPO Foundation The International Centers for Precision Oncology Foundation (ICPO) is a nonprofit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation´s aim is to gain momentum for Radiotheranostics in cancer care worldwide and scale global patient access to this innovative therapy.
About EANM The European Association of Nuclear Medicine is the largest non-profit medical organization dedicated to nuclear medicine in Europe. Since its establishment in 1985, the EANM has consistently aimed to provide an interactive platform for the sharing and discussion of cutting-edge developments in the field. The EANM collaborates with nuclear medicine professionals, national societies, EU institutions, international bodies, industry, and medical societies to leverage nuclear medicine's benefits for patient care.
About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways
About RayzeBio and Bristol Myers Squibb RayzeBio, Inc., a wholly-owned subsidiary of Bristol Myers Squibb Company, is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Sources 1. Hendifar AE, Mehr SH, McHaffie DR. Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Pancreas. 2022;51(3):213-218. 2. Ramnaraign B, Sartor O. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. Oncologist. 2023;28(5):392- 401. 3. Clinicaltrial.gov 4. Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48(13):4350-4368
Press photo: RLT Angels logo
Media contact ICPO Foundation Susanne Simon, Head of Communication & Community Email: susanne.simon@icpo.foundation Website: www.icpo.foundation
Media contact RLT Angels AssociationsWebsite: www.rlt-angels.com
Attachments
2025_06_21 PR ICPO Co-founded RLT Angels final
RLT_Angels Photo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Week in Review: Meta reveals its Oakley smart glasses
Welcome back to Week in Review! Lots in store for you today, including Wix's latest acquisition, Meta's new smart glasses, a look at the new Digg, and much more. Have a great weekend! Smart specs: Meta and Oakley have teamed up on a new pair of smart glasses that can record 3K video, play music, handle calls, and respond to Meta AI prompts. They start at $399 and have double the battery life of Meta's Ray-Bans. A $499 limited-edition Oakley Meta HSTN model will be available starting July 11. Unicorn watch: Wix bought 6-month-old solo startup Base44 for $80 million in cash after it quickly gained traction as a no-code AI tool for building web apps. Created by a single founder and already profitable, Base44's rapid rise made scooping it up irresistible. Sand to the rescue: Finland just turned on the world's largest sand battery — yes, actual sand — which stores heat to help power the small town of Pornainen's heating system and cut its carbon emissions. The low-tech, low-cost system is built from discarded fireplace soapstone, is housed in a giant silo, and can store heat for weeks, proving you don't need fancy lithium to fight climate change. You just need a pile of hot rocks. This is TechCrunch's Week in Review, where we recap the week's biggest news. Want this delivered as a newsletter to your inbox every Saturday? Sign up here. We're back, baby: VanMoof is back from the brink with the S6, its first e-bike since bankruptcy — and it's sticking to its signature custom design, despite that being what nearly killed the company. Backed by McLaren tech and a beefed-up repair network, the new VanMoof promises smoother rides, smarter features, and (hopefully) fewer stranded cyclists. Space lasers: Baiju Bhatt, best known for co-founding Robinhood, is now building lasers in space. His new startup, Aetherflux, has raised $60 million to prove that beaming solar power from orbit isn't a fantasy, with a demo satellite set to launch next year and early backing from the Department of Defense. Oh no: One of SpaceX's Starship rockets exploded during a test in Texas, likely pushing back the vehicle's next launch, which had been tentatively set for June 29. SpaceX says the blast, caused by a pressurized tank failure, didn't injure anyone, but it's yet another setback in a rocky year for the company's ambitious mega-rocket program. That lossless feeling: Spotify's long-awaited lossless audio tier still hasn't launched, but fresh hints buried in the latest app code suggest that it's under active development and could be closer than ever. But with years of delays and no official timeline, fans might want to temper their excitement until Spotify confirms the rollout. I can Digg it: Digg's reboot has entered alpha testing with a fresh iOS app aimed at becoming an AI-era Reddit alternative. The app offers a clean, simple design with curated communities, AI-powered article summaries, and gamified features like 'Gems' and daily leaderboards. We want you: The U.S. Navy is speeding up how it works with startups, cutting red tape and zeroing in on real wins like saved time and better morale. Department of the Navy CTO Justin Fanelli says it's leading with problems, hunting for game-changing tech in AI, GPS, and system upgrades. And with Silicon Valley finally paying attention, the Navy's becoming a go-to partner for innovators ready to shake things up. Cash ain't king: Mark Zuckerberg is throwing out massive cash — up to $100 million — to lure top AI talent from OpenAI and DeepMind. But OpenAI's Sam Altman says none of his key people have bitten, praising his team's mission over money. Meanwhile, OpenAI keeps pushing ahead with new AI models and even hints at launching an AI-powered social app that could outpace Meta's own shaky attempts. San Francisco's latest startup saga? Cluely's after-party for YC's AI Startup School blew up on Twitter, drawing 2,000 party crashers, but it became the 'most legendary party that never happened' after getting shut down by cops before a single drink was spilled. Founder Roy Lee's viral marketing may have promised chaos, but the real party's waiting. Maybe once the weather warms up?
Yahoo
an hour ago
- Yahoo
Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say
Working to lose weight in your 40s and 50s may help to reduce your risk of developing a chronic disease, a new study reveals. Researchers based in the U.K. and Finland say they found health benefits in people who lost an average of 6.5 percent of their body weight in early middle age and maintained that weight loss throughout a period of 12 to 35 years. Those benefits especially include a lessened risk for cardiovascular disease and diabetes as well as an overall lower risk of death from chronic disease. 'The benefits of lifestyle-based weight management are widely discussed even though studies have found it surprisingly difficult to demonstrate health benefits beyond the prevention of diabetes,' University of Helsinki professor Dr. Timo Strandberg said in a statement. Strandberg was the lead author of the study which was published recently in the journal JAMA Network Open, the open-access journal of the American Medical Association. To reach these conclusions, the study tracked and analyzed the health of 23,000 white Europeans who were between the ages of 30 and 50 years old using data from three studies, conducted from 1985 to 1988, from 1964 to 1973, and between 2000 and 2013. They sorted the participants into four groups: people with persistent healthy weight, people who were overweight but became a healthy weight, people who were healthy and became overweight, and people who were overweight the entire time. 'Measurement of weight and height was conducted at a time when surgical and pharmacological weight-loss interventions were nearly nonexistent,' the authors noted. The cause of weight loss was not assessed, but given the age of the participants and lack of diagnosed disease, it was more likely intentional than caused by severe chronic conditions or frailty.' In one study, a reduction in body mass from overweight to normal weight over six years in mid-life was tied to a lower risk of developing chronic diseases. There was also a 48 percent lower risk for chronic illness compared to those who remained overweight, which largely held even after excluding participants who developed diabetes during follow-up. Another study showed a 57 percent risk for chronic illness. A third study, with the longest follow-up period, showed that weight loss in mid-life was associated with a 19 percent reduction in overall mortality. 'I'm certain that overall prevention of overweight and obesity starting in early life is absolutely the best thing to do,' Stranberg told The Independent. 'Our study indirectly proves this by showing that persistent healthy weight over the life-course is best.' He said that he hopes the findings will inspire people to see that lifestyle changes can lead to a longer life. 'This is particularly important today as more people are overweight than when the collection of our research data began 35 years ago,' he said in the statement.
Yahoo
2 hours ago
- Yahoo
Tesla (NasdaqGS:TSLA) Set To Enter Indian Market With First Showrooms In July
Tesla is set to make a significant shift, entering the Indian market in July 2025 with new showrooms. This expansion comes at a time when the company's stock price rose by 30% over the last quarter, amid flat market performance in the past week and a 10% rise over the past year. The entry into India is aimed at countering declining sales in Europe and China, which could have influenced investor sentiment. Despite challenges such as a recent lawsuit and executive changes, this regional expansion might add weight to the broader market uptrend. Tesla has 2 risks we think you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent announcement of Tesla's expansion into the Indian market is a significant development that could influence its broader growth narrative. Despite facing challenges in other regions, this move may provide a new revenue stream, potentially mitigating some of the pressures from decreasing sales in Europe and China. Over the past five years, Tesla's shares have seen a very large total return of 403.51%, illustrating substantial long-term growth. When comparing to the previous year, Tesla's share return also surpassed the market, which returned 10%, and the US Auto industry, which posted a 60.9% gain over the past year. This suggests persistent investor confidence in Tesla, supporting its trajectory even amid short-term volatility. The strategic entry into a new market such as India might bolster revenue and earnings forecasts, as analysts anticipate a 16.6% annual revenue growth over the next three years. However, potential risks including geopolitical uncertainties and leadership changes could impact execution. With Tesla's current share price at US$275.35, it is trading close to the analyst consensus price target of US$289.44, suggesting a modest upside of 4.9%. This share price movement reflects mixed sentiments among investors regarding the balance of growth potential and inherent risks. Tesla's diverse initiatives, ranging from autonomous vehicles to energy solutions, underline its pursuit of long-term profitability, suggesting a complex interplay of factors influencing its market position. Gain insights into Tesla's outlook and expected performance with our report on the company's earnings estimates. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:TSLA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Connectez-vous pour accéder à votre portefeuille
